MRK logo Merck & Co. +
Merck & Co.
+

Merck & Co. (MRK) Business News

Track Merck & Co. in real time with a live news feed covering Merck & Co. stock news, official press releases, company announcements, and an archive of historical Merck & Co. news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
2:10 PM | Friday | Jul 10, 2026 Business Wire

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

News Thumbnail
6:45 AM | Wednesday | Jul 1, 2026 Business Wire

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

News Thumbnail
6:45 AM | Monday | Jun 29, 2026 Business Wire

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

News Thumbnail
6:45 AM | Thursday | Jun 25, 2026 Business Wire

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

News Thumbnail
6:45 AM | Monday | Jun 22, 2026 Business Wire

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

News Thumbnail
6:45 AM | Thursday | Jun 18, 2026 Business Wire

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

News Thumbnail
6:45 AM | Wednesday | Jun 17, 2026 Business Wire

Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages

News Thumbnail
8:00 AM | Tuesday | Jun 16, 2026 Business Wire

Protillion Biosciences Announces Drug Discovery Collaboration with Merck

News Thumbnail
6:45 AM | Thursday | Jun 11, 2026 Business Wire

Merck Animal Health to Acquire TARGAN

News Thumbnail
8:00 AM | Monday | Jun 8, 2026 Business Wire

Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health

News Thumbnail
6:45 AM | Tuesday | Jun 2, 2026 Business Wire

Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

News Thumbnail

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Business Wire

2:10 PM | Friday | Jul 10, 2026

news photo
Loading...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Merck's anti-PD-1 therapies, each in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment for the treatment of adult patients with muscle-invasive bla.

Read full article redirect
2:10 PM | Friday | Jul 10, 2026

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Merck's anti-PD-1 therapies, each in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment for the treatment of adult patients with muscle-invasive bla.

Read full article arrow
News Thumbnail
6:45 AM | Wednesday | Jul 1, 2026

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4.

Read full article arrow
News Thumbnail
6:45 AM | Monday | Jun 29, 2026

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Agreement to Improve Treatment Access for People Living with HIV. Agreement will help state ADAP programs provide access to IDVYNSO.

Read full article arrow
News Thumbnail
6:45 AM | Thursday | Jun 25, 2026

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Trodelvy® (sacituzumab govitecan-hziy), Gilead's Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative.

Read full article arrow
News Thumbnail
6:45 AM | Monday | Jun 22, 2026

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2) evaluating tulisokibart (MK-7240), an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in patients with moderately to severely active UC. The study successfully met its primary endpoint of clinical remission according to the Modified Mayo Scor.

Read full article arrow
News Thumbnail
6:45 AM | Thursday | Jun 18, 2026

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine).

Read full article arrow
News Thumbnail
6:45 AM | Wednesday | Jun 17, 2026

Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.
J., USA (NYSE:MRK), today announced results from a new global survey of dog owners and veterinarians revealing challenges and pain points associated with diagnosing the underlying cause of allergic skin disease in dogs and its treatment. According to Pet Owner and Vet Perspectives on Canine Pruritus: A Global Survey, about one-thi.

Read full article arrow
News Thumbnail
8:00 AM | Tuesday | Jun 16, 2026

Protillion Biosciences Announces Drug Discovery Collaboration with Merck

Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)--Protillion Biosciences, Inc., a leader in lab-in-the-loop AI drug design, today announced the signing of a multi-target discovery collaboration and license agreement with Merck, known as MSD outside the United States and Canada. The agreement combines Protillion's proprietary platform with Merck's global expertise in the discovery of novel therapeutic candidates. “Merck is a global leader in biopharmaceutical innovation, making them an ideal partner to deploy.

Read full article arrow
News Thumbnail
6:45 AM | Thursday | Jun 11, 2026

Merck Animal Health to Acquire TARGAN

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.
J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for an undisclosed purchase price. Merck Animal Health has invested in TARGAN since 2017 and has.

Read full article arrow
News Thumbnail
8:00 AM | Monday | Jun 8, 2026

Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health

Business Wire

SAN DIEGO--(BUSINESS WIRE)-- #animalhealth--Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health.

Read full article arrow
News Thumbnail
6:45 AM | Tuesday | Jun 2, 2026

Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference.

Read full article arrow
News Thumbnail